Invent medic Sweden AB (“Invent Medic”) has filed a priority application to PRV and applied for design registration at EUIPO. Both documents present design versions of the company’s first product, TVS.
TVS has shown to significantly reduce urinary leakage in a clinical study, that was reported in March 2018. An average of 77% reduction in urine leakage was documented from the clinical study. The study had 97 participating women. In parallel with the clinical study, invent Medic has been working on establishing more visually viable versions of the TVS. Overall, the commercial versions include improvements in material consumption, and a more consumer-friendly appearance. Assuming the patent is approved, Invent Medic will hold product protection until 2038, and assuming approved design protection, Invent Medic will hold design protection for a maximum of 25 years.